FierceBiotech 4 jun 2026 Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2
FierceBiotech 4 jun 2026 As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too
FierceBiotech 4 jun 2026 From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’
FierceBiotech 4 jun 2026 Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer
FierceBiotech 3 jun 2026 Lilly, Boehringer to slash at least $1B each from planned investments in Germany
FierceBiotech 3 jun 2026 As Akeso takes center stage at ASCO, China biotech industry cements its coming of age
FierceBiotech 3 jun 2026 Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases
FierceBiotech 2 jun 2026 Foundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer combo
FierceBiotech 2 jun 2026 New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
FierceBiotech 2 jun 2026 ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
FierceBiotech 2 jun 2026 Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases
FierceBiotech 2 jun 2026 Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks